PATENT CLAIM ANALYSIS

Application Number: 16130787
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-01
Patent Classification: ["424", "085200"]

Abstract:
A novel approach to discover new drugs against MS and other autoimmune diseases is disclosed. The p40 family of cytokines has four members which include interleukin-12 (IL-12), the p40 monomer (p40), the p40 homodimer (p40 2 ), and the IL-23. To facilitate the studies on p40 2  and p40, neutralizing monoclonal antibodies (mAb) against mouse p40 2  and p40 were generated for the first time. MS and other autoimmune disease drug therapies including recombinant p40 and/or monoclonal antibody against p40 2  (mAb-p40 2  a3-1d) are disclosed.

Claim (Index 6):
The method of  claim 1 , wherein the administration ameliorates one or more of the autoimmune diseases selected from the group consisting of multiple sclerosis, lupus, thyrioditis, rheumatoid arthritis, Sjogren's syndrome, Addison's disease and combinations thereof.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 97.0
- Lexical Diversity: 1.71667
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['10840789', '11768582', '11234011', '11722312', '10514687']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7585487102861316
- 35 USC 102 Novelty (BERT): 0.5076950096981613
- Combined Prediction Score: 0.7334633402273346
- Mean Citation Score: 197.588962
- Max Citation Score: 221.48625
- Similarity Product: 127.8143239503354

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test